2 results
Approved WMORecruiting
The aim of this phase 2 study is to investigate the safety and efficacy of dazucorilant in the target ALS patient population.
Approved WMOCompleted
- To evaluate the efficacy of pitolisant ( 5, 10, 20,40mg/d in the Double Blind Period and 5, 10, 15, 20, 30, 40mg/d in the Open Label Period) in reducing residual Excessive Daytime Sleepiness (EDS) and the number of cataplectic episodes (for…